• 1
    Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657686.
  • 2
    Wiener J, Quinn JP, Bradford PA et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281: 517523.
  • 3
    Rodríguez-Baño J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in non-hospitalized patients. J Clin Microbiol 2004; 42: 10891094.
  • 4
    Pitout JDD, Hanson ND, Church DL, Laupland KB. Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum β-lactamases: the importance of community isolates with blaCTX-M genes. Clin Infect Dis 2004; 38: 17361741.
  • 5
    Munday CJ, Whitehead GM, Todd NJ, Campbell M, Hawkey PM. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum β-lactamases in York, UK. J Antimicrob Chemother 2004; 54: 628633.
  • 6
    Rodríguez-Baño J, Paterson DL. A change in the epidemiology of infections due to extended-spectrum β-lactamase-producing organisms. Clin Infect Dis 2006; 42: 935937.
  • 7
    Pitout JDD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 5259.
  • 8
    Romero L, López L, Rodríguez-Baño J, Ramón Hernández J, Martínez-Martínez L, Pascual A. Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum β-lactamases. Clin Microbiol Infect 2005; 11: 625631.
  • 9
    Hernández JR, Pascual A, Cantón R, Martínez-Martínez L, y Grupo de Estudio de Infección Hospitalaria (GEIH). Escherichia coli y Klebsiella pneumoniae productores de betalactamasas de espectro extendido en hospitales españoles (proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin 2003; 21: 7782.
  • 10
    Ma L, Ishii Y, Chang FY, Yamaguchi K, Ho M, Siu LK. CTX-M-14, a plasmid-mediated CTX-M type extended-spectrum β-lactamase isolated from Escherichia coli. Antimicrob Agents Chemother 2002; 46: 19851988.
  • 11
    Bou G, Cartelle M, Tomas M et al. Identification and broad dissemination of the CTX-M-14 β-lactamase in different Escherichia coli strains in the northwest area of Spain. J Clin Microbiol 2002; 40: 40304036.
  • 12
    Hernández JR, Martínez-Martínez L, Cantón R, Coque MT, Pascual A, The Spanish Group for Nosocomial Infections (GEIH). Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain. Antimicrob Agents Chemother 2005; 49: 21222125.
  • 13
    Rodríguez-Baño J, Navarro MD, Romero L et al. Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006; 42: 3745.
  • 14
    Pitout JDD, Gregson DB, Church DL, Elsayed S, Laupland KB. Community-wide outbreaks of clonally related CTX-M-14 β-lactamase-producing Escherichia coli in the Calgary Health Region. J Clin Microbiol 2005; 43: 28442849.
  • 15
    Leflon-Guibot V, Jurand C, Bonacorsi S et al. Emergence and spread of three clonally related virulent isolates of CTX-M-15-producing Escherichia coli with variable resistance to aminoglycosides and tetracycline in a French geriatric hospital. Antimicrob Agents Chemother 2004; 48: 37363742.
  • 16
    Oteo J, Navarro C, Cercenado E et al. Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol 2006; 44: 23592366.
  • 17
    Mirelis B, Navarro F, Miró E, Mesa RJ, Coll P, Prats G. Community transmission of extended-spectrum β-lactamase. Emerg Infect Dis 2003; 9: 10241025.
  • 18
    Valverde A, Coque MT, Sánchez-Moreno MP, Rollán A, Baquero F, Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situation in Spain. J Clin Microbiol 2004; 42: 47694775.
  • 19
    Rodrigues C, Shukla U, Jog S, Mehta A. Extended-spectrum β-lactamase-producing flora in healthy persons. Emerg Infect Dis 2005; 6: 981982.
  • 20
    Pallecchi L, Malossi M, Mantella A et al. Detection of CTX-M-type β-lactamase genes in fecal Escherichia coli isolates from healthy children in Bolivia and Peru. Antimicrob Agents Chemother 2004; 48: 45564561.
  • 21
    Calbo E, Romaní V, Xercavins M et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum β-lactamases. J Antimicrob Chemother 2006; 57: 780783.
  • 22
    Astal Z, Sharif FA, Abdallah SA, Fahd MI. Extended-spectrum beta-lactamases in Escherichia coli isolated from community-acquired urinary tract infections in the Gaza Strip, Palestine. Ann Saudi Med 2004; 24: 5557.
  • 23
    Rodríguez-Baño J, Navarro MD, Romero L et al. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43: 14071414.
  • 24
    Baquero F, Cercenado E, Cisterna R et al. Patrones de sensibilidad a antimicrobianos de Enterobacteriaceae causantes de infecciones intraabdominales en España: resultados del estudio SMART 2003. Rev Esp Quimioter 2006; 19: 5159.
  • 25
    Colodner R, Rock W, Chazan B, Keller N, Guy N, Raz R. Risk factors for the development of extended-spectrum β-lactamase-producing bacteria in non-hospitalized patients. Eur J Clin Microbiol Infect Dis 2004; 23: 163167.
  • 26
    Ben-Ami R, Schwaber MJ, Navon-Venezia S et al. Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis 2006; 42: 925934.
  • 27
    Rodríguez-Baño J, Navarro MD, Romero L et al. Community-acquired bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli: an emerging clinical challenge. Clin Microbiol Infect 2005; 11 (suppl 2): 7273.
  • 28
    Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29: 6265.
  • 29
    De Cueto M, López L, Hernández JR, Morillo C, Pascual A. In vitro activity of fosfomycin against extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae: a comparison of susceptibility testing procedures. Antimicrob Agents Chemother 2006; 50: 368370.
  • 30
    Lagacé-Wiens PR, Nichol KA, Nicolle LE et al. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate. J Antimicrob Chemother 2006; 57: 12621263.
  • 31
    Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; 56: 451454.
  • 32
    Ho PL, Chan WM, Tsang KWT, Wong SSY, Yuong K. Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case–control study of risk factors and outcomes. Scand J Infect Dis 2002; 34: 567573.
  • 33
    Metan G, Zarakolu P, Cakir B, Hascelik C, Uzun O. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents 2005; 26: 254257.
  • 34
    Tan BH, Tan AL. Community-acquired bacteremia with an ESBL-producing Escherichia coli strain—a case report. Int J Infect Dis 2002; 6: 318319.
  • 35
    Borer A, Gilad J, Menashe G, Peled N, Riesenberg K, Schlaellfer F. Extended-spectrum beta-lactamase-producing Enterobacteriaceae strains in community-acquired bacteremia in Southern Israel. Med Sci Monit 2002; 8: CR44CR47.
  • 36
    Hernández JR, Velasco C, Romero L, Martínez-Martínez L, Pascual A. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain. Int J Antimicrob Agents 2006; 28: 457459.
  • 37
    Rodriguez-Villalobos H, Malaviolle V, Frankard J, De Mendonca R, Nonhoff C, Struelens MJ. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 2006; 57: 771774.
  • 38
    Morosini MI, Garcia-Castillo M, Coque TM et al. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006; 50: 26952699.